Work

Myeloid CD209 Drives Tumor Immune Evasion and Resistance to PD-1 Blockade Through ICAM-2–Mediated T-Cell Mechanosuppression

Year: 2026
Type: article
Abstract: Resistance to PD-1–based immunotherapy remains a major challenge in cancer treatment, especially in immunologically “cold” tumors characterized by T-cell exclusion and impaired T-cell effector function. Mechanical processes impact T-cell activity, and mechanical perturbations may represent a distinct mode of immune suppression. Here, we identified CD209, a myeloid-expressed C-type lectin receptor, as a mechanosuppressive regulator of antitumor T-cell immunity. CD209 was selectively enriched in tumor-infiltrating M2-like macrophages and monocytes, and elevated CD209 expression was associated with poor clinical response to PD-1 blockade and immune dysfunction and exclusion across multiple cancer types. Mechanistically, CD209 directly engaged ICAM-2 on T cells and activated ROCK1–ERM signaling. This interaction increased T-cell cortical stiffness, destabilized T cell–antigen presenting cell interactions, and attenuated T-cell receptor signaling. Blocking the CD209–ICAM-2–ERM pathway restored T-cell activation and promoted CD8+ T-cell infiltration and effector function in both in vivo mouse models and ex vivo human tumor systems. Importantly, CD209 blockade enhanced the response to PD-1 inhibition and overcame resistance to PD-1–based immunotherapy in refractory and immunologically “cold” tumor models. Together, these findings define a myeloid-derived mechanical immune checkpoint and reveal T-cell mechanosuppression as a targetable mechanism of tumor immune evasion and immunotherapy resistance.
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: green
OpenAlex ID: W7125606423
FWCI:
Cites: 81
Cited by:
Related to: 10